Latest News and Press Releases

Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases

Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases